Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PIPERACILLIN TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PIPERACILLIN TAZOBACTAM.
OMNIPEN (AMPICILLIN) vs Piperacillin-Tazobactam
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Category A/B
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic + Beta-Lactamase Inhibitor